I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| natural killer cell | 11 studies | 19% ± 4% | |
| CD16-positive, CD56-dim natural killer cell, human | 8 studies | 18% ± 3% | |
| CD8-positive, alpha-beta T cell | 7 studies | 18% ± 3% | |
| plasma cell | 6 studies | 27% ± 7% | |
| CD16-negative, CD56-bright natural killer cell, human | 6 studies | 18% ± 3% | |
| epithelial cell | 6 studies | 27% ± 12% | |
| non-classical monocyte | 5 studies | 31% ± 14% | |
| plasmablast | 4 studies | 44% ± 21% | |
| B cell | 4 studies | 22% ± 2% | |
| CD4-positive, alpha-beta T cell | 4 studies | 20% ± 3% | |
| classical monocyte | 4 studies | 26% ± 8% | |
| plasmacytoid dendritic cell | 4 studies | 24% ± 5% | |
| conventional dendritic cell | 3 studies | 33% ± 12% | |
| hematopoietic precursor cell | 3 studies | 22% ± 5% | |
| mature NK T cell | 3 studies | 17% ± 2% | |
| dendritic cell | 3 studies | 38% ± 15% | |
| goblet cell | 3 studies | 22% ± 4% |
